Video
Dr. Lerner on the pivotal OLYMPUS trial of Jelmyto in UTUC
Author(s):
“Of the 42 patients who achieved a complete response, 41 of those were evaluable for duration of response, which was the focus of the manuscript that was just published last month,” says Seth P. Lerner, MD.
Video Player is loading.
In this video, Seth P. Lerner, MD, discusses the background of the OLYMPUS trial, which has now released its final report. The phase 3 trial supported the FDA approval of mitomycin-containing reverse thermal gel (UGN-101; Jelmyto) for the treatment of patients with low-grade upper tract urothelial cancer.
Lerner is a professor in the Scott Department of Urology and Beth and Dave Swalm Chair in urologic oncology at the Baylor College of Medicine Medical Center in Houston, Texas.
Related Videos
PSMA PET and treatment intensification in mHSPC
Mark Edney, MD, highlights pending telehealth legislation
The importance of PSADT in high-risk, biochemically recurrent prostate cancer
Christina Ching, MD, on overcoming barriers to follow-up after pediatric stone surgery
Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
Helen L. Bernie, DO, MPH, on the FDA’s labeling changes for testosterone products
Expert outlines advantages of batteryless sacral neuromodulation device
Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
Amy E. Krambeck, MD, on what’s needed to improve safety, efficacy of HoLEP
Related Content
